心脑血管病防治2024，Vol.24Issue(4)：45-48,55,5.DOI:10.3969/j.issn.1009-816x.2024.04.011
代谢组学技术在心肌梗死生物标志物筛选中的研究进展
Research progress of metabolomics in screening biomarkers of myocardial infarction
王慧星 1盛佳洁 1李萌2
作者信息
- 1. 310053 杭州,浙江中医药大学第二临床医学院
- 2. 310013 杭州,浙江医院医学检验科
- 折叠
摘要
Abstract
Myocardial infarction is the ischemic necrosis of the myocardium caused by coronary artery obstruction,with a high incidence and mortality rate.Metabolic dysfunction can indicate an imbalance in myocardial energy supply and utilization,which is closely related to the occurrence,development,and prognosis of cardiovascular diseases.Currently,metabolomics technology has been applied in the study of myocardial infarction.By analyzing the types,quantities,and patterns of small-molecule metabolites in patients,metabolomics provides technical methods and ideas for the screening of biomarkers of diagnosis and prognostic for myocardial infarction.This article reviews the recent research progress of biomarkers in myocardial infarction using metabolomics technology.关键词
心肌梗死/代谢组学/生物标志物/诊断/预后Key words
Myocardial infarction/Metabolomics/Biomarker/Diagnosis/Prognosis引用本文复制引用
王慧星,盛佳洁,李萌..代谢组学技术在心肌梗死生物标志物筛选中的研究进展[J].心脑血管病防治,2024,24(4):45-48,55,5.
